1. Introduction {#s0005}
===============

Acute viral respiratory tract infection (also known as the common cold) is the most prevalent disease in humans, and is frequently associated with acute exacerbation of asthma. Most common colds are caused by respiratory viruses such as rhinovirus, influenza virus, parainfluenza virus, coronavirus, and respiratory syncytial virus \[[@bb0005]\].

Epithelial cells constitute the upper and lower airways\' front-line defenses against inhaled microbial pathogens. The efficient physical barrier formed by these cells is complemented by the mucociliary escalator, which also contributes significantly to defense of the airways against potentially harmful inhaled physical, chemical and biological agents \[[@bb0010]\]. After infecting the airway epithelium, human rhinovirus and influenza A virus trigger both innate and adaptive immune responses that are crucial for efficient antiviral control \[[@bb0015], [@bb0020], [@bb0025]\]. Airway epithelial cells also have an important role in the local regulation of the inflammatory response to viruses by releasing a variety of pleiotropic cytokines and chemokines. The cytokines (such as IL-1 and IL-6) exert a number of actions in the airways, whereas the chemokines (such as CCL5, CCL20, CXCL1, CXCL8, and CXCL10) contribute to the recruitment and activation of selected inflammatory cell populations (including neutrophils, eosinophils, dendritic cells, lymphocytes and natural killer cells) \[[@bb0030],[@bb0035]\].

Airway epithelial cells sense potentially dangerous inhaled materials through the latter\'s interactions with pattern recognition receptors, such as Toll-like receptors (TLRs) \[[@bb0040]\]. Toll-like receptor 3 (TLR3) recognizes double-stranded RNA (dsRNA), and thus is especially relevant to the airway epithelial cells\' response to rhinovirus and influenza A virus \[[@bb0045], [@bb0050], [@bb0055], [@bb0060]\]. This receptor is expressed in the endosomal compartments of dendritic cells and macrophages \[[@bb0065]\], and is also detected on the surface and in the cytoplasm of airway epithelial cells; as such TLR3 probably contributes to regulation of the cells\' innate response \[[@bb0070]\].

Seaweed products have been used in traditional Chinese herbal medicine for at least the last 500 years. Fucoidans constitute the main class of polysaccharide found in brown algae. They contain high levels of [l]{.smallcaps}-fucose and sulfate ester groups, and exert a variety of antiviral \[[@bb0075],[@bb0080]\], anti-inflammatory \[[@bb0085]\] and immunomodulatory effects \[[@bb0090],[@bb0095]\]. In particular, fucoidans are known to be ligands for class A scavenger receptors (SR-A), which also belong to the pattern recognition receptor family. It is known that SR-A is a cell surface receptor for dsRNA, and so may also be involved in antiviral immune responses \[[@bb0100]\]. To the best of our knowledge, the fucoidans\' effects on the release of inflammatory mediators induced by TLR3 activation have not previously been characterized. The objective of the present study was to assess the effects of a marine-sourced fucoidan solution (MFS) from *Ascophyllum nodosum* on the mRNA expression and protein production of cytokines, chemokines and prostaglandin E~2~ (PGE~2~) by human primary bronchial epithelial cells following TLR3 activation by Poly(I:C) (a synthetic analog of dsRNA) \[[@bb0105],[@bb0110]\].

2. Materials and methods {#s0010}
========================

2.1. Materials {#s0015}
--------------

Antibiotics (penicillin, streptomycin, gentamycin, vancomycin, amphotericin, and ceftazidim), DMSO, [l]{.smallcaps}-glutamine, heat-inactivated fetal calf serum, bovine pancreas protease, and HEPES were purchased from Sigma-Aldrich (St-Quentin Fallavier, France). Roswell Park Memorial Institute (RPMI) 1640 medium, Dulbecco\'s Modified Eagle\'s medium (DMEM) high-glucose DMEM, and bovine serum albumin were bought from Eurobio Biotechnology (Les Ulis, France). High-molecular-weight Poly(I:C) was obtained from InvivoGen (Toulouse, France). Bronchial epithelial cell growth medium (BEGM, supplemented with growth factors and antibiotics), and MycoZap™ were purchased from Lonza (Walkersville, MD, USA). Trypsin 0.25% EDTA was obtained from Gibco® (Thermo Fisher Scientific, Villebon sur Yvette, France). Culture flasks for epithelial cell culture were from TPP® (Trasadingen, Swiss) and Biocoat collagen-coated culture flasks were purchased from Corning® (Sigma-Aldrich, St-Quentin Fallavier, France). All the other cell culture plastics were from CML (Nemours, France).

Untreated sea water drawn from the Atlantic Ocean (off the coast of Brittany, France, by Yslab, Quimper, France) was prepared as follows: sand and carbon filtering, UV treatment, and sterilizing filtration (pore size: 1-0.45-0.2 μm). To lower the solution\'s tonicity, the seawater\'s salinity was reduced to 15 g·kg^−1^ by dilution with purified water.

Ascophyscient® fucoidan-rich *Ascophyllum nodosum* extract was purchased from Algues&Mer (Ouessant, France). The *Ascophyllum nodosum* seaweed had grown in a zone covered by the UNESCO World Network of Biosphere Reserves and that had achieved a "good ecological status" according to the European Union\'s Water Framework Directive 2000/60/EC. The seaweed\'s thallus was used for fucoidan extraction. The main extraction steps were polyphenol trapping, aqueous extraction, solid/liquid separation, microparticle removal (by filtration), alginate precipitation and removal, further filtration, demineralization, depolymerization, and atomization. The extract\'s total sugar content was 40% by weight (according to Dubois\' method \[[@bb0115]\], using fucose as the sugar standard), and the total sulfate level was 17% (as determined by liquid chromatography, as described in the International Standard ISO 10304). The remaining components were uronic acid and ash. The [l]{.smallcaps}-fucopyranose structure of the backbone of the fucoidan extracted from *Ascophyllum nodosum* has been previously described, and features alternating α(1 → 3) and α(1 → 4) linkages \[[@bb0120],[@bb0125]\]. The mean molecular weight was 18,940 g/mol as determined with high performance size exclusion chromatography coupled to a refractive index detector.

To prepare the MFS, *Ascophyllum nodosum* extract was dissolved to a final concentration of 0.1% (m/v) in diluted sea water. This concentration was chosen on the basis of previous work \[[@bb0130], [@bb0135], [@bb0140], [@bb0145]\].

2.2. Isolation and culture of human primary bronchial epithelial cells {#s0020}
----------------------------------------------------------------------

The use of resected lung tissue for in vitro experiments was approved by the local institutional review board (*Comité de Protection des Personnes Ile-de-France VIII*, Boulogne-Billancourt, France; reference: DC-2010-1221), and the patients gave their informed consent before the surgical procedure. Lung tissue samples were obtained from 17 patients (10 males and 7 females; 6 smokers, 10 former smokers, 1 non-smoker; mean ± standard error (SD) age: 65.5 ± 7.2 years; FEV1: 74.4 ± 23.7%; pack-years: 36 ± 13; 7 had COPD) undergoing surgical resection for lung carcinoma and who had not received prior chemotherapy. None of the subjects had been treated with immunosuppressants or corticosteroids before surgery. Proximal segmental bronchi collected from sites distant from the tumor were placed in high-glucose DMEM supplemented with [l]{.smallcaps}-glutamine, 10% fetal calf serum, HEPES, antibiotics, and antifungal drugs (penicillin, streptomycin, gentamycin, vancomycin, amphotericin, ceftazidim and MycoZap™), and were stored at +4 °C (for bacterial decontamination) for at least 3 days. The bronchial mucus was removed, and the bronchus was cut lengthwise before the addition of protease (10 mg·mL^−1^) overnight at +4 °C. On the following day, the luminal surface of each bronchus sample was gently scratched in order to detach epithelial cells into the culture medium. After centrifugation of the cell suspension, the cell pellet was resuspended in 30 mL of supplemented high-glucose DMEM and placed in a culture flask for 2 h at 37 °C in a 5% CO~2~ atmosphere. The supernatant was recovered and placed in a BioCoat collagen-coated flask. On the following day and then every other day, the culture medium was replaced with 15 mL of antibiotic-free high-glucose DMEM and 15 mL of BEGM (referred to hereafter as BEGM-DMEM). When the cells reached confluence (usually after 7 days of culture), they were detached from the plate with trypsin, centrifuged, and resuspended in BEGM-DMEM in a 24-well plate (1 mL per well) for 24 h prior to exposure to pharmacological agents.

2.3. Treatment of bronchial epithelial cells {#s0025}
--------------------------------------------

The 24-well plates were washed, and 1 mL of fresh BEGM-DMEM was added per well. Cells were incubated with either sodium chloride 0.9% (control) or MFS for 1 h (200 μL/well). The solutions were then removed, and the cells were incubated in 2 mL of culture medium in the absence or presence of 10 μg·mL^−1^ high-molecular-weight Poly(I:C) cells for 24 h. The cell culture supernatants were then collected and stored at −80 °C for later analysis.

2.4. Cytokine and chemokine assays {#s0030}
----------------------------------

The production of selected chemokines and cytokines was assessed by measuring their concentrations in the bronchial epithelial cells\' supernatants using commercially available ELISAs (Duoset Development System, R&D Systems Europe, Lille, France). The limit of detection was 1 pg.mL^−1^ for IL-1β, 4 pg·mL^−1^ for IL-1α and CCL22, 8 pg·mL^−1^ for TNF-α, CCL2 and CXCL5, 9 pg·mL^−1^ for IL-6, 16 pg·mL^−1^ for CCL5, CCL20, CXCL1, and CXCL8, and 32 pg·mL^−1^ for IL-12/IL-23. Levels of PGE~2~ were determined using a commercially available ELISA (Cayman Chemical Europe, Tallinn, Estonia).

2.5. Cytotoxicity assays {#s0035}
------------------------

Cell viability was assessed by measuring LDH release (CytoTox96® Non-Radioactive Cytotoxicity Assay from Promega, Madison, USA).

2.6. Reverse transcriptase - quantitative polymerase chain reaction {#s0040}
-------------------------------------------------------------------

Total RNA was prepared using TRIzol® reagent (Life Technologies, Saint Aubin, France), and RNA was extracted according to the manufacturer\'s instructions. The RNA\'s intactness was determined by running an aliquot of each sample on an Experion automated electrophoresis station (Bio-Rad, Marnes-la-Coquette, France). The RNA concentration was determined using a Biowave DNA spectrophotometer (Biochrom, Cambridge, UK). Next, 1 μg of total RNA was reverse-transcribed using a SuperScript® III First-strand SuperMix kit (Life Technologies).

Specific TaqMan® arrays based on predesigned reagents (Life Technologies) were used to assay cytokine and chemokine transcripts (customized TaqMan® array 96-well FAST Plate, Applied Biosystems, Foster City, USA). Reverse transcriptase-quantitative PCR was performed using Gene Expression Master Mix (Life Technologies) with 20 ng of cDNA in a StepOnePlus thermocycler (Life Technologies). The thermal cycling conditions were as follows: initial denaturation at 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. The housekeeping gene hypoxanthine phosphoribosyltransferase (*HPRT1*) was used for signal normalization.

2.7. Statistical analysis {#s0045}
-------------------------

Statistical analysis was performed using Prism software (version 6, GraphPad Software, La Jolla, CA, USA). A one-way analysis of variance for repeated measures (or a Friedman test, when appropriate) followed by pos*t*-tests or a paired Student\'s *t*-test (or a Wilcoxon test, when appropriate) were used to compare treatments (MFS and Poly(I:C)) with controls.

3. Results {#s0050}
==========

3.1. Cytotoxicity {#s0055}
-----------------

A one-hour incubation with MFS and then 24 h in culture medium alone was not associated with elevated LDH release by the epithelial cells (relative to controls), thus demonstrating the absence of cytotoxicity ([Table 1](#t0005){ref-type="table"} ).Table 1Cytotoxicity after incubation with marine-sourced fucoidan solution (MFS) for 1 h, followed by 24 h in culture medium. Cytotoxicity was measured using an LDH release assay. The data correspond to the mean ± SEM of 7 to 10 independent experiments.Table 1Treatment% of LDH releaseSodium chloride 0.9%0.36 ± 0.09MFS0.41 ± 0.12Poly(I:C)0.93 ± 0.23Poly(I:C) + MFS0.53 ± 0.20

3.2. Effects of the MFS on cytokine expression by bronchial epithelial cells {#s0060}
----------------------------------------------------------------------------

Exposure to Poly(I:C) was associated with the elevated expression (relative to control experiments) of genes coding for the cytokines CCL5, CCL20, CCL22, CXCL1, CXCL5, CXCL8, IL-1β, IL-6, and TNF-α ([Fig. 1](#f0005){ref-type="fig"} ). However, pre-incubation of epithelial cells with MFS inhibited the Poly(I:C)-induced elevation in the expression of these genes. The elevated gene expression of CCL22 was completely blocked by MFS.Fig. 1Effects of the marine-sourced fucoidan solution (MFS) on the Poly(I:C)-induced expression of cytokines by human bronchial epithelial cells. Bronchial epithelial cells were incubated with the MFS or NaCl 0.9% (control) for 1 h, followed by 24 h in culture medium in the absence or presence of Poly(I:C) 10 μg·mL^−1^. The data are expressed as the median (range) of three independent paired experiments.Fig. 1

3.3. Effects of MFS on cytokine and chemokine production by bronchial epithelial cells {#s0065}
--------------------------------------------------------------------------------------

Incubation with MFS did not generally alter the baseline production of cytokines and chemokines by non-stimulated cells ([Table 2](#t0010){ref-type="table"} ). However, incubation with MFS was associated with a slight relative increase in the baseline production of IL-6, CXCL8 and CCL20 ([Table 2](#t0010){ref-type="table"}). Poly(I:C) induced a marked elevation of the production of all the measured cytokines/chemokines (except for IL-12/IL-23) to a varying extent (from 2.5-fold for IL-1β and CXCL1 to 250-fold for CCL5) ([Table 2](#t0010){ref-type="table"}). Pre-incubation with MFS significantly inhibited the production of IL-1α, IL-1β, TNF-α and IL-6 but not that of IL-12/IL-23 ([Table 2](#t0010){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"} ). Similarly, pre-incubation with MFS inhibited the Poly(I:C)-induced production of some chemokines (CCL5, CCL22, CXCL1, CXCL5 and CXCL8) but not others (CCL2 and CCL20) ([Table 2](#t0010){ref-type="table"}, [Fig. 3](#f0015){ref-type="fig"} ).Table 2Effects of a marine-sourced fucoidan solution (MFS) on the production of cytokines by human bronchial epithelial cells.Human bronchial epithelial cells were incubated for 1 h in the presence of a Marine-sourced fucoidan solution (MFS) or sodium chloride 0.9% (control) before being stimulated with Poly (I:C) (10 μg·mL^−1^) for 24 h. The concentrations of the cytokines are expressed in pg/10^6^ cells. The data correspond to the mean ± SEM for the number (n) of independent experiments indicated. nd: not determined.Table 2CytokinenControlMFSPOLY (I:C)MFS + POLY (I:C)IL-1α6137 ± 53116 ± 47740 ± 290[⁎](#tf0005){ref-type="table-fn"}374 ± 121[⁎](#tf0005){ref-type="table-fn"}IL-1β1054 ± 28nd138 ± 30[⁎](#tf0005){ref-type="table-fn"}69 ± 19[⁎⁎](#tf0010){ref-type="table-fn"}TNF-α1217 ± 5nd542 ± 146[⁎⁎](#tf0010){ref-type="table-fn"}301 ± 74[⁎⁎⁎](#tf0015){ref-type="table-fn"}IL-66824 ± 4101138 ± 454[⁎](#tf0005){ref-type="table-fn"}37,436 ± 11274[⁎](#tf0005){ref-type="table-fn"}22,876 ± 8503[⁎](#tf0005){ref-type="table-fn"}IL-12/IL-233604 ± 247602 ± 277501 ± 208654 ± 355CCL26182 ± 90394 ± 2092112 ± 541[⁎⁎](#tf0010){ref-type="table-fn"}1950 ± 579CCL5618 ± 811 ± 54556 ± 1552[⁎](#tf0005){ref-type="table-fn"}3781 ± 1219[⁎](#tf0005){ref-type="table-fn"}CCL206546 ± 2491036 ± 223[⁎](#tf0005){ref-type="table-fn"}4722 ± 891[⁎⁎](#tf0010){ref-type="table-fn"}4840 ± 756CCL22127 ± 2nd41 ± 11[⁎](#tf0005){ref-type="table-fn"}14 ± 2[⁎⁎](#tf0010){ref-type="table-fn"}CXCL16/1049,377 ± 11,66855,568 ± 10,827142,614 ± 35149[⁎](#tf0005){ref-type="table-fn"}109,981 ± 23871[⁎⁎](#tf0010){ref-type="table-fn"}CXCL512267 ± 103nd2927 ± 643[⁎⁎](#tf0010){ref-type="table-fn"}1871 ± 522[⁎⁎⁎](#tf0015){ref-type="table-fn"}CXCL864985 ± 15546819 ± 1860[⁎](#tf0005){ref-type="table-fn"}81,956 ± 19093[⁎⁎](#tf0010){ref-type="table-fn"}67,256 ± 20169[⁎](#tf0005){ref-type="table-fn"}[^1][^2][^3]Fig. 2Effect of the marine-sourced fucoidan solution (MFS) on Poly(I:C)-induced cytokine release (IL-1α, IL-1β, TNF-α, and IL-6) by human bronchial epithelial cells. Bronchial epithelial cells were incubated with the MFS or NaCl 0.9% (control) for 1 h, followed by 24 h in culture medium in the absence or presence of Poly(I:C) 10 μg·mL^−1^. The data are expressed as the mean ± SEM of 6 to 12 independent, paired experiments. The significance thresholds were \*p \< 0.05, \*\*p \< 0.01, and \*\*\**p* \< 0.001.Fig. 2Fig. 3Effect of the marine-sourced fucoidan solution (MFS) on chemokine release (CCL5, CCL22, CXCL1, CXCL5, and CXCL8) by human bronchial epithelial cells. Bronchial epithelial cells were incubated with the MFS or NaCl 0.9% (control) for 1 h, followed by 24 h in culture medium in the absence or presence of Poly(I:C) 10 μg·mL^−1^. Data correspond to the mean ± SEM of 6 to 12 independent paired experiments. The significance thresholds were \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001.Fig. 3

3.4. Effects of MFS on the production of PGE~2~ by bronchial epithelial cells {#s0070}
-----------------------------------------------------------------------------

Exposure to MFS did not alter the low baseline level of PGE~2~ production by non-stimulated bronchial epithelial cells (data not shown) but did markedly inhibit the Poly(I:C)-induced production of PGE~2~ ([Fig. 4](#f0020){ref-type="fig"} ). This observation was in line with MFS\'s inhibition of the Poly(I:C)-associated elevation in COX-2 expression ([Fig. 4](#f0020){ref-type="fig"}).Fig. 4Effect of the marine-sourced fucoidan solution (MFS) on the mRNA expression of COX-2 and the production of PGE~2~ by human bronchial epithelial cells. Bronchial epithelial cells were incubated with the MFS or NaCl 0.9% (control) for 1 h, followed by 24 h in culture medium in the absence or presence of Poly(I:C) 10 μg·mL^−1^. Data correspond as the median (range) of three independent paired experiments (A) or the mean ± SEM of 17 (B) independent paired experiments. The significance threshold was \*\*\*p \< 0.001.Fig. 4

4. Discussion {#s0075}
=============

The objective of the present study was to explore the effects of a seawater solution of depolymerized fucoidans from *Ascophyllum nodosum* on human bronchial epithelial cells. An hour of exposure to MFS was enough to inhibit the Poly(I:C)-induced elevation in cytokine/chemokine mRNA expression and protein production, mRNA expression of COX-2, and the production of PGE~2~ by human bronchial epithelial cells for 24 h.

Fucoidans are abundant, sulfated polysaccharides found only in brown algae. Over the last few decades, fucoidans purified from different species of brown alga have been extensively studied because of their broad spectrum of desirable biological activities, including anticoagulant, antithrombotic, antitumor, anti-inflammatory, and immunomodulatory effects \[[@bb0150]\]. In a recent in vitro study of RAW 264.7 macrophages, fucoidans purified from the marine brown alga *Chnoospora minima* were found to inhibit (i) the lipopolysaccharide (LPS)-induced production of nitrous oxide and PGE~2~ via the downregulation of inducible nitric oxide synthase (iNOS) and COX-2 expression, and (ii) the production of TNF-α, IL1-β, and IL-6 \[[@bb0155]\]. Furthermore, sulfated polysaccharides extracted from other brown seaweeds (*Sargassum hemiphyllum* and *Sargassum horneri*) were shown to reduce pro-inflammatory cytokine production (IL-1β, IL-6 and TNF-α), NO production, and the expression of IL-1β, iNOS, and COX-2 and NF-κB (p65) in LPS-stimulated RAW 246.7 macrophages \[[@bb0160],[@bb0165]\]. In macrophages, the mechanisms underlying the fucoidans\' anti-inflammatory actions have yet to be elucidated. However, it has been reported that fucoidans regulated signaling pathways involving MAP kinases and NF-κB \[[@bb0170]\]. Since the MFS did not influence epithelial cell viability, its inhibitory effect was not due to non-specific toxicity.

The present study is the first to have demonstrated that fucoidans (extracted from *Ascophyllum nodosum* and dissolved in diluted seawater) also have anti-inflammatory effects on human primary bronchial epithelial cells. In particular, the MFS\'s inhibition of the effects on bronchial epithelial cells of a synthetic viral-like dsRNA (Poly(I:C)) suggests that fucoidans might dampen the epithelium\'s inflammatory response to viral infections. In addition to the inhibition of the production of various pro-inflammatory cytokines (IL-1α, IL-1β, TNFα, and IL-6) and chemokines (CCL5, CCL22, CXCL1, CXCL5 and CXCL8), the inhibition of PGE~2~ may have beneficial effect by reducing mucus secretion \[[@bb0175],[@bb0180]\]. Further studies are needed to determine whether or not exposure to MFS lowers mucus secretion in the nasal epithelium.

In addition to fucoidans, other algal polysaccharides reportedly exert antiviral activities through various mechanisms of action, such the inhibition of virus binding or internalization and the suppression of DNA replication and/or protein synthesis \[[@bb0185],[@bb0190]\]. Scavenger receptors have been described as functional co-receptors of both TLR3 and TLR4 \[[@bb0195], [@bb0200], [@bb0205]\], and the process of endocytosis might lie at the interface between several underlying mechanisms. Indeed, activation of the SR-A-fucoidan complex is dependent on endocytosis \[[@bb0210]\], and endosomal internalization of cell-surface TLR3 is critical for the epithelial cells\' response to Poly(I:C) \[[@bb0070]\]. In the present study, the SR-A-fucoidan complex may have been endocytosed (along with TLR3) during the one-hour exposure to MFS, and thus would no longer have been present on the cell surface when Poly(I:C) was added - thus blocking the response to this TLR agonist. However, further studies are required to determine the exact mechanism of action.

The airway epithelium is continuously exposed to a multitude of noxious challenges in inhaled air, and has an important role in regulating the local inflammatory response to viral infections of the upper and lower airways. Earlier research has shown that human bronchial epithelial cell cultures accurately recapitulate the functional characteristics of human nasal epithelial cells, and so could therefore serve as a surrogate for the latter. Indeed, the two cell types have morphologic, histologic and functional similarities. Their respective ciliary activities react to various agonists and antagonists in a similar manner \[[@bb0215]\]. In experiments on nasal and bronchial epithelial cells harvested from children with cystic fibrosis (with a wide variety of *CFTR* mutations), the cell types\' stimulated and inhibited levels of CFTR were similar \[[@bb0220]\]. In other studies of human bronchial and nasal epithelial cells, levels of cytokine and chemokine release in vitro were similar for both non-stimulated cells and cells stimulated with TNF-α, IL-1β, IL-13 or even rhinovirus infection \[[@bb0225], [@bb0230], [@bb0235]\]. Indeed, nasal epithelial cells showed much the same cytokine responses as bronchial epithelial cells when exposed to rhinovirus under air-liquid interface culture or submerged culture conditions; this observation is of particularly relevance to the present study \[[@bb0235]\]. Taken as a whole, these findings strongly suggest that (i) nasal and bronchial airway epithelial cells can be used interchangeably, and thus (ii) our observation of MFS\'s anti-inflammatory effects on bronchial epithelial cells can be legitimately transposed to nasal epithelial cells.

Most common colds are caused by respiratory viruses whose number, diversity and antigenic variability limit the development of an effective vaccine. Although the infection is usually self-limiting, it affects people of all age groups and still causes significant morbidity. At present, the standard therapy for the common cold is general care and the treatment of symptoms. Over-the-counter antihistamines are commonly used to relieve symptoms but have a short-term beneficial effect and do not appear to be effective in children \[[@bb0240]\]. Over-the-counter nasal decongestants are also used, although their effectiveness and safety in children and the clinical relevance of their small symptomatic effect in adults have yet to be demonstrated \[[@bb0245]\]. Furthermore, the available evidence does not support the use of intranasal corticosteroids for symptomatic relief from the common cold \[[@bb0250]\]. It was recently shown that iota-carrageenan (a sulfated polysaccharide found in some species of red seaweed) exerts potent activity against respiratory viruses by directly binding to the infectious particles; however, carrageenan does not enter the host cell and is not expected to exert pharmacologic or immune activities \[[@bb0255]\]. Although iota-carrageenan was found to be effective as nasal spray in three clinical trials \[[@bb0005],[@bb0255],[@bb0260]\], it failed to achieve statistically significant outcomes for the primary and secondary endpoints in the most recent study \[[@bb0265]\]. Nasal irrigation with saline is often employed as an adjunct treatment for acute upper respiratory tract infections - particularly in children - and might relieve the symptoms to some extent \[[@bb0270]\]. The MFS assessed here is a ready-to-use, topically applied solution that combines nasal saline irrigation and the topical delivery of fucoidans.

In conclusion, our study results suggest that fucoidans could be used to prevent or treat viral-induced airway inflammation. The MFS may therefore combine the symptomatic benefits of local irrigation with anti-inflammatory activity in the treatment of the common cold.
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[^1]: *p* \< 0.05 (significant treshold for MFS vs. Control).

[^2]: *p* \< 0.01 (significant treshold for Poly(I:C) vs Control)

[^3]: *p* \< 0.001 (significant treshold for MFS + Poly(I:C) vs Poly(I:C)).
